MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.

Baldo, V

MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. [electronic resource] - Vaccine May 2007 - 3955-61 p. digital

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

0264-410X

10.1016/j.vaccine.2007.02.045 doi


Adjuvants, Immunologic--adverse effects
Adolescent
Adult
Chronic Disease--therapy
Double-Blind Method
Female
Humans
Influenza A Virus, H3N2 Subtype--immunology
Influenza B virus--immunology
Influenza Vaccines--adverse effects
Influenza, Human--complications
Male
Middle Aged
Polysorbates--adverse effects
Risk Factors
Squalene--adverse effects
Vaccines, Subunit--adverse effects